Endocrinology Drugs Market Size Expected to Increase by USD 36551.24 Million: Rising Incidence of Endocrine Disorders Remains Key Growth Driver

NEW YORK, December 7, 2022 /PRNewswire/ — The global endocrinology drugs market the size should increase by $36,551.24 million from 2022 to 2027, according to Technavio. The growth momentum of the market will accelerate at a CAGR of 7.82% during the forecast period. This report provides analysis and information for effective decision making. Download sample report

Endocrinology Drugs Market – Key Driver and Major Challenge

The increased incidence of endocrine disorders is driving the growth of the endocrinology drugs market. The prevalence of endocrine disorders such as diabetes is increasing worldwide, especially in low- and middle-income countries. The incidence of these disorders is high in the aging population. With advances in healthcare technology, the average life expectancy of people has increased dramatically across the world. This has led to an increase in the aging population around the world. Thus, the rising incidence of endocrine disorders and expanding aging population are expected to drive the growth of the global endocrinology drugs market over the forecast period.

The expiring patents of major endocrinology drugs are hampering the growth of the endocrinology drugs market. Endocrinology drugs have been on the market since 1995, and many of the approved drugs available at the time are about to expire. For example, Lantus, one of the most prescribed insulins in the world, lost its patent in February 2015. Similarly, NovoLog/NovoRapid’s patent expired in 2014. These upcoming patent expirations paved the way for generic drugs, causing branded drug manufacturers to lose market share. This is expected to reduce the growth potential of the market over the forecast period.

Technavio has identified key trends, drivers and challenges, along with competitive analysis to help clients improve their strategies to stay ahead of competitors. Buy the report for detailed market information.

Five major endocrinology pharmaceutical companies

• Acerus Pharmaceuticals Corp. – The company offers endocrinology drugs such as Natesto.

• Bayer AG – The company offers endocrinology drugs such as finerenone.

• Beta Cell NV – The company offers endocrinology drugs such as BetaGraft.

• Eli Lilly and Co. – The company offers endocrinology drugs such as Humatrope.

• Endo International Plc – The company offers endocrinology drugs such as fortesta.

The story continues

Other Key Suppliers

Get lifetime access to our Technavio Insights! Subscribe to our Basic plan billed annually at $5000

Endocrinology Drugs Market Therapy Field Outlook (Revenue, USD Million, 2022-2027)

• Diabetes drugs – size and forecast 2022-2027

• HGH – size and forecast 2022-2027

• Thyroid hormone disorders – size and forecast 2022-2027

• Others – size and forecast 2022-2027

Endocrinology Drugs Market Distribution Channel Outlook (Revenue, USD Million, 2022-2027)

• Hospital pharmacies – size and forecast 2022-2027

• Retail pharmacies – size and forecast 2022-2027

• Online pharmacies – size and forecast 2022-2027

Geographical Outlook of the Endocrinology Drugs Market (Revenue, USD Million, 2022-2027)

• North America – size and forecast 2022-2027

• Europe – size and forecast 2022-2027

• Asia – size and forecast 2022-2027

• Rest of the world (ROW) – size and forecast 2022-2027

Discover the contribution of each segment summarized in concise infographics and detailed descriptions. View sample PDF report

What are the key data covered in this Endocrinology Drugs market report?

• Market CAGR over the forecast period 2023-2027

• In-depth information on the factors that will drive the growth of the Endocrinology Drugs Market between 2023 and 2027

• Accurate estimation of the Endocrinology Drugs market size and its contribution to the parent market.

• Accurate predictions on upcoming trends and changes in consumer behavior

• Growth of the Endocrinology Drugs Industry through North America, Europe, Asiaand the rest of the world (ROW)

• An in-depth analysis of the market competitive landscape and detailed vendor information

• Comprehensive details of the factors that will challenge the growth of the Endocrinology Drugs Market vendors

Related Reports

• The biosimilars market is expected to grow at a CAGR of 23% between 2022 and 2027. The market size is expected to increase by $42,227.12 million. The price advantage of biosimilars over biologics is notably driving the growth of the market, although factors such as market access barriers for biosimilars may hamper the growth of the market.

• The botanical drugs and plant derivatives market the size should increase by $15.89 billion from 2021 to 2026, and the growth momentum of the market will accelerate at a CAGR of 7.25%. The increase in government initiatives is particularly driving the growth of the botanical and plant-derived drugs market, although factors such as low acceptance by physicians may hamper the growth of the market.

Contents:

1. Summary

2 Market landscape

3 Market sizing

4 Historical market size

5 Five forces analysis

6 Market Segmentation by Therapeutic Area

7 Market Segmentation by Distribution Channel

8 Customer Landscape

9 Geographic landscape

10 drivers, challenges and trends

11 Supplier landscape

12 Vendor Analysis

13 Appendix

About Technavio

Technavio is a global leader in technology research and consulting. Their research and analysis focuses on emerging market trends and provides actionable insights to help companies identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialist analysts, Technavio’s reporting library consists of over 17,000 reports and counts, spanning 800 technologies, spanning 50 countries. Their customer base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing customer base relies on Technavio’s comprehensive coverage, in-depth research, and actionable market intelligence to identify opportunities in existing markets and potentials and assess their competitive positions in changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Manager
USA: +1 844 364 1100
UK: +44 203 893 3200
E-mail: [email protected]
Website: www.technavio.com/

Show original content to download multimedia:https://www.prnewswire.com/news-releases/endocrinology-drugs-market-size-to-grow-by-usd-36551-24-million-increase-in-the-incidence-of-endocrine-disorders- rest-key-engine-of-growth—technavio-301695948.html

SOURCETechnavio